Barriers to acceptance of the human papillomavirus prophylactic vaccine

Jill Blumenthal, Katherine P. Heyman, Robin M. Trocola, Brian Slomovitz

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. In June 2006, the US Food and Drug Administration approved Gardasil, a quadrivalent HPV 6, 11, 16 and 18 recombinant vaccine. Indicated for young girls and women aged 9 to 26, Gardasil is the first vaccine approved to prevent transmission of HPV types 16 and 18. In order to move toward universal acceptance of the HPV vaccine by the general population, both mandated HPV vaccination and HPV vaccination-specific issues must be addressed. Identifying and understanding factors associated with the acceptance of the HPV vaccine has been and will continue to be important so physicians can assist parents and adolescents in their decision to refuse or accept the vaccine. Despite the potential social and cultural barriers to a universal HPV vaccination program, numerous studies have indicated a willingness among many women to accept the vaccine for their daughters. It is clear that education will play an important role in the implementation of such a vaccination program.

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalJournal of Pediatric Infectious Diseases
Volume3
Issue number3
StatePublished - 2008
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Vaccination
Human papillomavirus 18
Vaccines
Human papillomavirus 11
Human papillomavirus 6
Synthetic Vaccines
Human papillomavirus 16
United States Food and Drug Administration
Sexually Transmitted Diseases
Nuclear Family
Parents
Physicians
Education
Population
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Keywords

  • Acceptance
  • Barriers
  • HPV
  • Human papillomavirus vaccine
  • Sexually transmitted disease

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Infectious Diseases

Cite this

Barriers to acceptance of the human papillomavirus prophylactic vaccine. / Blumenthal, Jill; Heyman, Katherine P.; Trocola, Robin M.; Slomovitz, Brian.

In: Journal of Pediatric Infectious Diseases, Vol. 3, No. 3, 2008, p. 159-165.

Research output: Contribution to journalArticle

Blumenthal, Jill ; Heyman, Katherine P. ; Trocola, Robin M. ; Slomovitz, Brian. / Barriers to acceptance of the human papillomavirus prophylactic vaccine. In: Journal of Pediatric Infectious Diseases. 2008 ; Vol. 3, No. 3. pp. 159-165.
@article{49d7b5d2f4ae4151a10c43c0bac5d325,
title = "Barriers to acceptance of the human papillomavirus prophylactic vaccine",
abstract = "Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. In June 2006, the US Food and Drug Administration approved Gardasil, a quadrivalent HPV 6, 11, 16 and 18 recombinant vaccine. Indicated for young girls and women aged 9 to 26, Gardasil is the first vaccine approved to prevent transmission of HPV types 16 and 18. In order to move toward universal acceptance of the HPV vaccine by the general population, both mandated HPV vaccination and HPV vaccination-specific issues must be addressed. Identifying and understanding factors associated with the acceptance of the HPV vaccine has been and will continue to be important so physicians can assist parents and adolescents in their decision to refuse or accept the vaccine. Despite the potential social and cultural barriers to a universal HPV vaccination program, numerous studies have indicated a willingness among many women to accept the vaccine for their daughters. It is clear that education will play an important role in the implementation of such a vaccination program.",
keywords = "Acceptance, Barriers, HPV, Human papillomavirus vaccine, Sexually transmitted disease",
author = "Jill Blumenthal and Heyman, {Katherine P.} and Trocola, {Robin M.} and Brian Slomovitz",
year = "2008",
language = "English (US)",
volume = "3",
pages = "159--165",
journal = "Journal of Pediatric Infectious Diseases",
issn = "1871-0336",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Barriers to acceptance of the human papillomavirus prophylactic vaccine

AU - Blumenthal, Jill

AU - Heyman, Katherine P.

AU - Trocola, Robin M.

AU - Slomovitz, Brian

PY - 2008

Y1 - 2008

N2 - Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. In June 2006, the US Food and Drug Administration approved Gardasil, a quadrivalent HPV 6, 11, 16 and 18 recombinant vaccine. Indicated for young girls and women aged 9 to 26, Gardasil is the first vaccine approved to prevent transmission of HPV types 16 and 18. In order to move toward universal acceptance of the HPV vaccine by the general population, both mandated HPV vaccination and HPV vaccination-specific issues must be addressed. Identifying and understanding factors associated with the acceptance of the HPV vaccine has been and will continue to be important so physicians can assist parents and adolescents in their decision to refuse or accept the vaccine. Despite the potential social and cultural barriers to a universal HPV vaccination program, numerous studies have indicated a willingness among many women to accept the vaccine for their daughters. It is clear that education will play an important role in the implementation of such a vaccination program.

AB - Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. In June 2006, the US Food and Drug Administration approved Gardasil, a quadrivalent HPV 6, 11, 16 and 18 recombinant vaccine. Indicated for young girls and women aged 9 to 26, Gardasil is the first vaccine approved to prevent transmission of HPV types 16 and 18. In order to move toward universal acceptance of the HPV vaccine by the general population, both mandated HPV vaccination and HPV vaccination-specific issues must be addressed. Identifying and understanding factors associated with the acceptance of the HPV vaccine has been and will continue to be important so physicians can assist parents and adolescents in their decision to refuse or accept the vaccine. Despite the potential social and cultural barriers to a universal HPV vaccination program, numerous studies have indicated a willingness among many women to accept the vaccine for their daughters. It is clear that education will play an important role in the implementation of such a vaccination program.

KW - Acceptance

KW - Barriers

KW - HPV

KW - Human papillomavirus vaccine

KW - Sexually transmitted disease

UR - http://www.scopus.com/inward/record.url?scp=52249089036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52249089036&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:52249089036

VL - 3

SP - 159

EP - 165

JO - Journal of Pediatric Infectious Diseases

JF - Journal of Pediatric Infectious Diseases

SN - 1871-0336

IS - 3

ER -